help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 2, 96-110, February 2006; doi:10.1634/theoncologist.11-2-96
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 The Influence of Endocrine Effects of Adjuvant Therapy on Quality of Life O...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knobf, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knobf, M. T.

The Influence of Endocrine Effects of Adjuvant Therapy on Quality of Life Outcomes in Younger Breast Cancer Survivors

M. Tish Knobf

Yale School of Nursing, New Haven, Connecticut, USA

Key Words. Breast cancer • Fertility • Gonadal toxicity • Menopause • Quality of life

Correspondence: M. Tish Knobf, Ph.D., R.N., F.A.A.N, A.O.C.N, Yale School of Nursing, 100 Church Street South, New Haven, Connecticut 06536-0740, USA. Telephone: 203-737-2357; Fax: 203-737-2414; e-mail: tish.knobf{at}yale.edu; Web site: http://www.nursing.yale.edu

Significance. There are 2.2 million breast cancer survivors, and approximately 25%–30% of newly diagnosed women each year are <50 years of age. Adjuvant therapy has prolonged survival, but the quality of that survival is influenced by persistent and late effects of therapy. Knowledge of treatment outcomes will assist in the design of interventions to prevent or manage persistent and late effects in survivors.

Purpose. The purpose of this paper is to review the incidence of gonadal toxicity associated with adjuvant chemotherapy, side effects of endocrine therapy, quality of life outcomes, fertility concerns, and options to preserve fertility in young (<35 years) and young midlife (35–50 years) breast cancer survivors.

Results. Alkylating agent–based chemotherapy causes destruction of primordial follicles and impairment of follicular maturation resulting in temporary preservation of menses, reversible amenorrhea, irregular menses (perimenopause), or irreversible amenorrhea (ovarian failure—menopause). Younger women have a lower risk for amenorrhea with chemotherapy because of sufficient follicular stores, although the gonadal toxicity will result in an earlier than expected menopause. Premature menopause is associated with poorer quality of life, decreased sexual functioning, menopausal symptom distress, psychosocial distress related to fertility concerns, infertility, and uncertainty about late effects of premature menopause. Routine discussion about the menopausal experience, risks for infertility, and fertility preservation options is recommended.

Implications for Practice. This review identified adverse treatment outcomes for young and young midlife breast cancer survivors that can be minimized or prevented with targeted interventions.




This article has been cited by other articles:


Home page
 Clin Nurs ResHome page
M. Cappiello, R. S. Cunningham, M. Tish Knobf, and D. Erdos
Breast Cancer Survivors: Information and Support After Treatment
Clin Nurs Res, November 1, 2007; 16(4): 278 - 293.
[Abstract] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2006 by AlphaMed Press.